Skip to content

house · Committee report

H. Rept. 119-725

TO REAUTHORIZE THE KAY HAGAN TICK ACT, AND FOR OTHER PURPOSES

2026-07-02

Committees

Associated legislation

Text

Purpose and Summary

H.R. 4348, introduced on July 10, 2025, by Representatives Chris Smith (R-NJ) and Lloyd Doggett (D-PA), reauthorizes the National Strategy and Regional Centers of Excellence in Vector- Borne Disease and the Centers for Disease Control and Prevention's (CDC) cooperative agreements with health departments in areas at high risk of vector-borne diseases through Fiscal Year 2030.

Background and Need for Legislation

Vector-borne diseases (VBDs) pose an escalating threat to the public's health within the United States. A vector is a mosquito, tick, or flea that can spread pathogens, and the annual number of reported cases of vector-borne disease has doubled over the past two decades.\1\ In 2019, 50,865 of the 56,045 VBDs cases reported to CDC were tickborne diseases.\2\ Lyme Disease currently accounts for more than 70 percent of these reported tick disease cases.\3\ It is estimated that about 476,000 people are diagnosed and treated for Lyme disease annually in the U.S.\4\ --------------------------------------------------------------------------- \1\Ctrs. for Disease Control and Prevention (CDC), National Public Health Strategy to Prevent and Control Vector-Borne Diseases in People (Dec. 22, 2025), https:www.cdc.gov/vector-borne-diseases/php/data- research/national-strategy/index.html. \2\Id. \3\CDC, A National Public Health Framework for the Prevention and Control of Vector-Borne Diseases in Humans (Sept. 2020), https:// www.cdc.gov/vector-borne-diseases/media/pdfs/ Brochure_National_Framework_VBDs-P.pdf. \4\Supra note 1. --------------------------------------------------------------------------- The mosquitos, ticks, and fleas that carry dangerous diseases are expanding their habitat within the United States.\5\ To date, there are no vaccines and limited treatment options for tickborne illnesses.\6\ The VBD National Strategy is led by the Department of Health and Human Services and has six participating federal departments, allowing for a coordinated approach to VBD prevention and control. --------------------------------------------------------------------------- \5\Id. \6\Johns Hopkins Bloomberg School of Public Health, Ticks Pose an Increasing Health Risk (Apr. 30, 2025), https://publichealth.jhu.edu/ 2025/tickborne-diseases-in-the-us. --------------------------------------------------------------------------- In addition to the development of the VBD National Strategy, the 2019 Kay Hagan Tick Act established Regional Centers of Excellence in Vector-Borne Disease, located at universities in California, Florida, Texas, and Wisconsin. The law and directs CDC to enter into cooperative agreements across the United States with health departments in areas at high risk of vector-borne diseases.\7\ These cooperative agreements support better data collection and analysis, earlier detection and diagnosis, as well as improve treatments and awareness around VBDs. --------------------------------------------------------------------------- \7\Office of the Assistant Secretary for Health (OASH), Vector Borne Disease National Strategy, The Kay Hagan Tick Act (Aug. 27, 2023), https://health.gov/about-oash/io-programs- initiatives/innovationx/vector-borne-disease-national-strategy/kay- hagan-tick-act. ---------------------------------------------------------------------------

Committee Action

On April 15, 2026, the Subcommittee on Health held a hearing on H.R. 4348. The title of the hearing was ``Healthier America: Legislative Proposals to Improve Public Health.'' The Subcommittee received testimony from: Jamie Ulmer, MA, President and CEO, Healthcare Network Rachel F. Brem, MD, FACR, FSBI, Co-Founder, Chief Medical Officer, Brem Foundation to Defeat Breast Cancer and Professor and Vice-Chair Emeritus, The George Washington University Holly Ahern, MS, MT(ASCP), Associate Professor of Microbiology, State University of New York Adirondack Amy L. Ronneberg, MBA, Chief Executive Officer, National Marrow Donor Program Brian Wallach & Sandra Abrevaya, Co- Founders, I AM ALS Rene Quashie, JD, Vice President, Digital Health, Consumer Technology Association On May 13, 2026, the Subcommittee on Health met in open markup session and forwarded H.R. 4348, without amendment, to the full Committee by a voice vote. On May 21, 2026, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 4348, without amendment, favorably reported to the House by a record vote of 48 yeas and 0 nays.

Committee Votes

Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. The following reflects the record votes taken during the Committee consideration: Oversight Findings and Recommendations Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held a hearing and made findings that are reflected in this report. New Budget Authority, Entitlement Authority, and Tax Expenditures Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 4348 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.

Congressional Budget Office Estimate

Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available. Federal Mandates Statement The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act. Statement of General Performance Goals and Objectives Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to reauthorize the National Strategy and Regional Centers of Excellence in Vector-Borne Disease and the Centers for Disease Control and Prevention's (CDC) cooperative agreements with health departments in areas at high risk of vector-borne diseases through Fiscal Year 2030. Duplication of Federal Programs Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 4348 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111-139 or the most recent Catalog of Federal Domestic Assistance. Related Committee and Subcommittee Hearings Pursuant to clause 3(c)(6) of rule XIII, the following related hearings were used to develop or consider H.R. 4348: On April 15, 2026, the Subcommittee on Health held a legislative hearing on H.R. 4348. The title of the hearing was ``Healthier America: Legislative Proposals to Improve Public Health.'' The Subcommittee received testimony from: Jamie Ulmer, MA, President and CEO, Healthcare Network; Rachel F. Brem, MD, FACR, FSBI, Co-Founder, Chief Medical Officer, Brem Foundation to Defeat Breast Cancer and Professor and Vice-Chair Emeritus, The George Washington University; Holly Ahern, MS, MT(ASCP), Associate Professor of Microbiology, State University of New York Adirondack; Amy L. Ronneberg, MBA, Chief Executive Officer, National Marrow Donor Program; Brian Wallach & Sandra Abrevaya, Co-Founders, I AM ALS; and, Rene Quashie, JD, Vice President, Digital Health, Consumer Technology Association. On April 21, 2026, the Subcommittee on Health held a hearing on H.R. 4348. The title of the hearing was ``The Fiscal Year 2027 Department of Health and Human Services Budget.'' The Subcommittee received testimony from: The Honorable Robert F. Kennedy Jr., Secretary, U.S. Department of Health and Human Services. Committee Cost Estimate Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available. Earmark, Limited Tax Benefits, and Limited Tariff Benefits Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 4348 contains no earmarks, limited tax benefits, or limited tariff benefits. Advisory Committee Statement No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation. Applicability to Legislative Branch The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act. Section-by-Section Analysis of the Legislation Section 1. Reauthorization of programs Section 1 reauthorizes the National Strategy and Regional Centers of Excellence in Vector-Borne Disease and the CDC's cooperative agreements with health departments in areas at high risk of vector-borne diseases through Fiscal Year 2030. Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (existing law proposed to be omitted is enclosed in black brackets, new matter is printed in italics, and existing law in which no change is proposed is shown in roman): PUBLIC HEALTH SERVICE ACT * * * * * * * TITLE III--GENERAL POWERS AND DUTIES OF PUBLIC HEALTH SERVICE * * * * * * * Part B--Federal-State Cooperation * * * * * * * SEC. 317U. NATIONAL STRATEGY AND REGIONAL CENTERS OF EXCELLENCE IN VECTOR-BORNE DISEASES. (a) In General.--The Secretary shall-- (1)(A) ensure the development and implementation of a national strategy to address vector-borne diseases, including tick-borne diseases, that-- (i) identifies and assesses gaps and any unnecessary duplication in federally-funded programs; and (ii) identifies strategic goals to address such diseases and appropriate benchmarks to measure progress toward achieving such goals; and (B) update such strategy, as appropriate; and (2) coordinate programs and activities, including related to data collection, research, and the development of diagnostics, treatments, vaccines, and other related activities, to address vector-borne diseases, including tick-borne diseases, across the Department of Health and Human Services and with other Federal agencies or departments, as appropriate. (b) Consultation.--In carrying out subsection (a)(1), the Secretary shall consult with [the Tick-Borne Disease Working Group established under section 2062 of the 21st Century Cures Act (42 U.S.C. 284s) and other individuals, as appropriate] appropriate individuals, such as-- (1) epidemiologists with experience in vector-borne diseases; (2) representatives of patient advocacy and research organizations that focus on vector-borne diseases, including such organizations that have demonstrated experience in related research, public health, data collection, or patient access to care; (3) health information technology experts or other information management specialists; (4) clinicians, entomologists, vector management professionals, public health professionals, and others with expertise in vector-borne diseases; and (5) researchers, including researchers with experience conducting translational research. (c) Centers of Excellence.--The Secretary, in coordination with the Director of the Centers for Disease Control and Prevention, shall award grants, contracts, or cooperative agreements to institutions of higher education for the establishment or continued support of regional centers of excellence in vector-borne diseases to address vector-borne diseases, including tick-borne diseases, by-- (1) facilitating collaboration between academia and public health organizations for public health surveillance, prevention, and response activities related to vector-borne diseases, including tick-borne diseases; (2) providing training for public health entomologists and other health care professionals, as appropriate, to address vector-borne diseases, including tick-borne diseases; (3) conducting research to develop and validate prevention and control tools and methods, including evidence-based and innovative, evidence-informed tools and methods to anticipate and respond to disease outbreaks; or (4) preparing for and responding to outbreaks of vector-borne diseases, including tick-borne diseases, including by increasing capacity to identify, report, prevent, and respond to such diseases. (d) Eligibility.--To be eligible to receive a grant, contract, or cooperative agreement under subsection (c), an entity shall submit to the Secretary an application at such time, in such manner, and containing such information as the Secretary may require, including a description of how the entity will conduct the activities described in such subsection. (e) Reports.-- (1) Program summary.--An entity receiving an award under subsection (c) shall, not later than one year after receiving such award, and annually thereafter, submit to the Secretary a summary of programs and activities funded under the award. (2) Progress report.--Not later than 4 years after the date of enactment of this section, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, a report on the progress made in addressing vector-borne diseases, including tick-borne diseases, through activities carried out under this section. (f) Authorization of Appropriations.--For the purpose of carrying out this section, there are authorized to be appropriated $10,000,000 for each of fiscal years [2021 through 2025] 2026 through 2030. * * * * * * * TITLE XXVIII--NATIONAL ALL-HAZARDS PREPAREDNESS FOR PUBLIC HEALTH EMERGENCIES * * * * * * * Subtitle C--Strengthening Public Health Surveillance Systems * * * * * * * SEC. 2822. ENHANCED SUPPORT TO ASSIST HEALTH DEPARTMENTS IN ADDRESSING VECTOR-BORNE DISEASES. (a) In General.--The Secretary, acting through the Director of the Centers for Disease Control and Prevention, may enter into cooperative agreements with health departments of States, political subdivisions of States, and Indian Tribes and Tribal organizations in areas at high risk of vector-borne diseases in order to increase capacity to identify, report, prevent, and respond to such diseases and related outbreaks. (b) Eligibility.--To be eligible to enter into a cooperative agreement under this section, an entity described in subsection (a) shall prepare and submit to the Secretary an application at such time, in such manner, and containing such information as the Secretary may require, including a plan that describes-- (1) how the applicant proposes to develop or expand programs to address vector-borne disease risks, including through-- (A) related training and workforce development; (B) programmatic efforts to improve capacity to identify, report, prevent, and respond to such disease and related outbreaks; and (C) other relevant activities identified by the Director of the Centers for Disease Control and Prevention, as appropriate; (2) the manner in which the applicant will coordinate with other Federal, Tribal, and State agencies and programs, as applicable, related to vector-borne diseases, as well as other relevant public and private organizations or agencies; and (3) the manner in which the applicant will evaluate the effectiveness of any program carried out under the cooperative agreement. (c) Authorization of Appropriations.--For the purposes of carrying out this section, there are authorized to be appropriated $20,000,000 for each of fiscal years [2021 through 2025] 2026 through 2030. * * * * * * * [all]

Source: https://api.congress.gov/v3/committee-report/119/hrpt/725